“Volume in Numbers…
Power from Volume”
Find Out MoreOur sites and Social Media platforms act as a podium for your company to talk to their audience – consumers.
We provide many portals for companies to host fully loaded comprehensive profiles, animated banner ads describing your company and its products in their true light, Videos, Business Plans, Executive Summaries, and PowerPoints. All of these features are provided free to the end user with no fees making it easy for your company to communicate and share resources with potential and active clients and consumers.

Planning, making strategies…
After successfull campaign…
Case Studies
Client Testimonials
News
- ZenaTech Reacts to ‘Unleashing U.S. Military Drone Dominance’ Memo — A Game-Changing Policy Directive for ZenaDrone
- Drone Applications for All Sectors
- ZenaTech Creates First Quantum Computing Prototype Enabling Disruptive AI Drone Speed and Precision for Future Commercial and US Defense Applications
- Alpha Modus (NASDAQ: AMOD) Receives Confirmation of Listing Transfer to Nasdaq Capital Market, Confirms NASDAQ Compliance, Defends Capital Integrity, and Asserts Preservation of Once-in-a-Generation Asset
- Alpha Modus Awarded New U.S. Patent Strengthening Its AI Retail Technology Portfolio
- Alpha Modus (NASDAQ: AMOD) Expands CashX to African Specialty Retailers as Strategic Beachhead into Diaspora Markets
- Alpha Modus (NASDAQ: AMOD) Expands CashX to African Specialty Retailers as Strategic Beachhead into Diaspora Markets
- ZenaTech Poised to Benefit from Historic US Defense Spending─$33 Billion for Drone and Autonomy Investments in ‘One Big Beautiful Bill’
- Exploring Drones with the Longest Flight Times
- Alpha Modus Featured in 2nd International Business Times Story
- Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals, was interviewed for a broadcast hosted by AdvisorShares.
- Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals, was interviewed for a broadcast hosted by New to The Street TV.
- RMX (Reticulate Micro) Secures GSA Schedule Placement, Enhancing Government Market Access
- IQSTD - IQSTEL Reports Strong Preliminary Q1 2025 Results: Revenue Growth, Margin Expansion, and Strategic Progress Toward NASDAQ Uplisting
- Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma